The January trend is off to a great start and it is historically bullish.
Historically, the first week of January is very important. There is a saying, "as the first week goes, so goes January. As January goes, so goes the year." When the first week of January is up strongly, the entire month of January is up strongly. The Nasdaq has a 100% winning streak since 1980 when the first week was up strong, the index was up for the month an average of 4.5%. The Dow and S&P were less consistent but both were up 75% of the time after a strong first week.
Historical facts and market maxims are great when they are not taken as hard and fast trading rules. They also tend to fail when confronted with things like government shutdowns, which we could see on the 19th.
We simply need to see how the current euphoria plays out. Monday was a smoke-clearing day. Investors were so crazy covering shorts and chasing prices last week, the market needed a day to rest and let the smoke clear so they could make plans for the rest of January.
The S&P continued its gains over 2,700 but the index is now more than 7% (179 points) over its 100-day average and a point of extreme divergence. Historically, this is the widest extreme in terms of points and probably in terms of percentage but I have no way of checking the prior percentage numbers.
With five days of consecutive gains the index is due for a rest. The S&P futures were down -4 points earlier but have recovered to only -1.50. The 2,700 level should be support on any material decline although I seriously doubt we will see that level again over the next five weeks.
The Dow is now 2,051 points above its 100-day average of 8.8%. That is another example of extreme divergence. The index traded in negative territory nearly all day but there was never any material decline. It was just a sideways day on mediocre volume while traders caught their breath.
The Nasdaq Composite continued to surge higher and is closing in on the 7,200 level. The index is well above its established trend and 7.6% (505 points) above its 100-day average. The big cap techs were all positive with the exception of QCOM, ADBE, BABA and AAPL but all of them only closed a few cents lower. The big gains were to the upside with PCLN, TSLA and AMZN posting double-digit gains.
The Nasdaq should find support in the 7,000 range.
The Russell 2000 recovered from a 12-point drop at the open to post a 2-point gain at the close. The decline knocked the index back to prior resistance at 1,550 and that level held as current support. If the small caps could move into rally mode, it would help sentiment for the entire market.
We have a busy economic calendar but none of these reports should move the market. Investors are going to be more focused on the approaching funding deadline and the headlines out of Washington.
The Q4 earnings begin on Friday with the big banks. JP Morgan, Wells Fargo, Blackrock and PNC Financial will set the stage for the rest of the sector.
I am bullish on the market longer-term but we could see some volatility over the next week. I doubt it will be material but we never know. I believe investors will want to remain invested through the Q4 earnings because of the upgraded guidance that includes plans for the tax reform savings. There will be increased dividends and buybacks and probably some M&A announcements. This should keep the market moving higher until the first three weeks of earnings are over. That is about where investors will begin to believe all the good news is already priced into the market. We could see some profit taking and then a new rebound into Q1 earnings where the actual results of the tax cuts will be released. After the Q1 earnings, we could have a rocky summer.
Enter passively, exit aggressively!
Send Jim an email
TIME HAS RUN OUT!!
LOCK IN YOUR SAVINGS!!!
SUBSCRIBE TO THE 2018 EOY NOW!
The options market isn’t waiting for you. And you shouldn’t wait to keep Option Investor coming at the lowest prices you’ll see for at least a year! There isn’t a minute to spare. Order now.
Each EOY subscriber will receive a genuine Morgan Dollar, which is thought to be one of the best looking silver coins ever minted. These make great presents!
Morgan Silver Dollar
Renew for as little as
$1.35 per day
NEW DIRECTIONAL CALL PLAY
NTGR - Netgear - Company Profile
NETGEAR, Inc. designs, develops, and markets innovative networking solutions and smart connected products for consumers, businesses, and service providers. The company operates in three segments: Retail, Commercial, and Service Provider. The Retail segment offers home WiFi networking solutions and smart connected products. The Commercial segment provides business networking, storage, and security solutions. The Service Provider segment offers made-to-order home networking hardware and software solutions, including 4G LTE hotspots sold to service providers for sale to their subscribers. The company also offers commercial business networking products, such as Ethernet switches, wireless controllers and access points, Internet security appliances, and unified storage products; broadband access products, including broadband modems, WiFi gateways, and WiFi hotspots; and smart home/Internet-of-Things connectivity and products comprising WiFi routers and home WiFi system, WiFi range extenders, powerline adapters and bridges, remote video security systems, and WiFi network adapters. It markets and sells its products through traditional retailers, online retailers, wholesale distributors, direct market resellers, value-added resellers, and broadband service providers worldwide. Company description from FinViz.com
Expected earnings February 6th.
Two weeks ago Amazon bought Blink. You may not have heard about Blink but they launched in 2016 with an inexpensive wireless camera and video doorbell. This is the hot new sector for video surveillance. You have probably heard about Ring video doorbells, which is a different company.
The point to this commentary is that Netgear is making the very popular Arlo security camera and sales are booming. Netgear also has 48% of the market for home routers.
With Amazon likely to go big in this category after the acquisition of Blink, that means Netgear is suddenly a target. Global Equities said Facebook, Google or even Apple could acquire Netgear because that gives them a top position in the space. Google would be the prime candidate because they could link the Arlo system to Google Home. It would also allow Google access to trillions of terabytes of data related to the home routers and networking equipment. Monitoring those devices would be like keeping their finger on the pulse of technology. They would know how many people are watching Netflix, how much data was being consumed by what subset of users, etc. This could be very important in their planning for the future.
Apple is not likely to make a play for Netgear because they do not do big acquisitions and Netgear has too many "common" products for Apple to manage. They would be more likely to buy Tesla or Netflix if they were going to make a big splash.
Facebook could find a way to use the Arlo system and that would be a significant branch away from their social media roots. I doubt they would want the networking business.
In reality, nobody has to buy Netgear for them to succeed. They are already successful and Arlo is an entirely new category for them and a category that is exploding in sales. When they report Q4 numbers they could be very high.
Shares spiked to $60 in mid December and traded sideways for the last three weeks. I believe shares are about to move higher.
Buy Mar $65 call, currently $2.56. initial stop loss $56.25.
Check the graphic below for any new stop losses in bright yellow. We need to always be prepared for an unexpected decline. Any items shaded in blue were previously closed.
Current Position Changes
UTX - United Technologies
The long put position was entered at the open on Tuesday.
DLTR - Dollar Tree
The long call position was closed at the open on Tuesday.
Original Play Recommendations (Alpha by Symbol)
ABBV - AbbVie - Company Profile
No specific news. AbbVie was granted a breakthrough designation on Upadacitinib for Atopic Dermatitus. Shares closed at a new high on Friday.
Original Trade Description: November 6th.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. Company description from FinViz.com.
Next expected earnings January 26th.
A lot of companies have 1-2 real drugs in the pipeline that may be approved. Several companies have one drug that could be a blockbuster and reach $1 billion in sales annually. AbbVie has multiple blockbusters in the pipeline and dozens of other drugs already in the market.
AbbVie was a spinoff from Abbott Laboratories in 2012 and they are doing great.
ABBV reported earnings of $1.41 that beat estimates for $1.39. Revenue of $7 billion missed estimates for $7.04 billion. They raised full year guidance from $5.44-$5.54 to $5.53-$5.55. They guided for 2018 earnings of $6.37 to $6.57. Analysts were expecting $5.53 for 2017 and $6.56 for 2018. The company raised its quarterly dividend by 11% to 71 cents.
AbbVie previously guided for sales of Humira to exceed $18 billion in 2020. In their earnings call they raised that guidance to $21 billion in 2020. Sales of Humira hit $4.7 billion in Q3 to put it on track for $18 billion two years earlier than prior guidance. That is just one drug. At the same time, they are projecting non-Humira sales to reach $35 billion in 2025. That is a risk adjusted assumption that some drugs will fail in trials. Without any failures they are projecting $47 million. The risk-adjusted number would put AbbVie in 9th place by revenue. The nominal number would put them in fifth place.
The company recently announced a deal with Amgen to resolve patent problems on Humira and push biosimilar competition well into the future. The company's confident that there would not be a biosimilar drug until 2021-2022 matched analyst estimates. This is a steep uphill battle for anyone trying to copy this drug.
In September AbbVie filed two new drug applications with the FDA and reported positive results on two drug trials. Shares have gained $12 in a week. On Monday, they reported studies on rheumatoid arthritis with the drug Upadacitinib had met all primary and secondary endpoints. In testing two different doses 40% of patients reported clinical remission after 12 weeks and 50% reported the same after 24 weeks, without any unforeseen side effects. These were patients that had failed to respond to conventional treatments. More than 23 million people are afflicted with this disease. This will be a blockbuster drug for AbbVie and they have many more in the pipeline.
The company received a favorable opinion on MAVIRET, a once daily Hep-C drug, from the European Medical Agency and the CHMP. This is an 8-week cure for Hep-C that will compete with Gilead's products.
Analysts claim AbbVie's pipeline is the strongest in the industry. The post earnings drop is a buying opportunity and shares are rebounding. The company's other drugs are going to be cash cows. Imbruvica generated $1.8 billion in sales in 2016 and could reach $7 billion annually over the next couple of years. Venclexta was approved in 2016 for leukemia and sales could peak at $3.5 billion a year. An experimental cancer drug called Rova-T could hit $5 billion a year when approved. A psoriasis drug called risankizumab could produce $4 billion a year and arthritis drug upadacitinib could peak at $3.5 billion.
Update 11/27: AbbVie was just notified that one of its groundbreaking lymphoma drugs had been accepted as a late-breaking abstract at the American Society of Hematology conference in early December. In all, the company will have a total of 28 abstracts presented across various hematologic malignancies. The conference if Dec 9-12th and should generate some positive headlines for the company.
Update 12/4: AbbVie said a phase 3 trial of its plaque psoriasis treatment, risankizumab, met all co-primary and ranked secondary endpoints. The company said no new safety signals were detected. "With a significant portion of risankizumab patients achieving high levels of skin clearance, these results add to the data supporting risankizumab's potential to be an impactful new treatment option for patients living with psoriasis. Shares tried to rally but the biotech sector was crashing with the Nasdaq.
Update 12/11: AbbVie said a phase 2 trial of Imbruvica, showed positive results for cGVHD after stem cells or bone marrow transplants. They also reported positive results for the same drug on Mantle Cell Lymphoma and chronic Lymphocytic Leukemia. The drug still has additional testing but it appears to be on track for successful adoption in various therapies.
Long Feb $95 call @ $3.75, see portfolio graphic for stop loss.
BOTZ - Robotics & AI ETF - Company Profile
No specific news. Monster rebound with the market and the chip sector.
Original Trade Description: October 24th
The Global X Robotics & Artificial Intelligence ETF seeks to invest in companies that potentially stand to benefit from increased adoption and utilization of robotics and artificial intelligence (AI), including those involved with industrial robotics and automation, non-industrial robots, and autonomous vehicles. The ETF seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Indxx Global Robotics & Artificial Intelligence Thematic Index.
The ETF has 28 stocks including NVDA, ISRG, TRMB, BRKS, IRBT, MZOR, Toshiba and Cyberdyne.
The ETF is somewhat slow moving since it just began trading in September. Volume has increased significantly to 2.59 million shares on Monday.
The key to this ETF and this position is that the stock rarely goes down and the options are cheap. There have only been 3 periods of decline in 2017 and each drop was only about 60 cents. The ETF is rising steadily since April but has recently been accelerating. If this continues, even allowing for some declines, that would equate to a nice gain by June and the option costs $1.45 at the money. This is not going to set the world on fire like a Facebook or Netflix but it should be dependable, stable gains. Obviously, past performance is no guarantee of future results.
Long June $24 call @ $1.45. See portfolio graphic for stop loss.
CAT - Caterpillar - Company Profile
No specific news. We dodged a bullet on CAT on Tuesday. Shares declined to $155.40 with our stop loss at $155. The stock then rebounded $11 to close at $166 on Monday. YeeHaw!!! This rocket ride is eventually going to end.
Original Trade Description: November 13th
Caterpillar Inc. manufactures and sells construction and mining equipment, diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives for heavy and general construction, rental, quarry, aggregate, mining, waste, material handling, oil and gas, power generation, marine, rail, and industrial markets. Its Construction Industries segment offers backhoe, compact, track-type, small and medium wheel, knuckleboom, and skid steer loaders; small and medium track-type, and site prep tractors; mini, wheel, forestry, small, medium, and large track excavators; and motorgraders, pipelayers, telehandlers, cold planers, asphalt pavers, compactors, road reclaimers, and wheel and track skidders and feller bunchers. The company's Resource Industries segment provides electric rope and hydraulic shovel, landfill and soil compactor, dragline, large wheel loader, machinery component, track and rotary drill, electronics and control system, work tool, hard rock vehicle and continuous mining system, scoop and hauler, wheel tractor scraper, large track-type tractor, and wheel dozer products; longwall, highwall, and continuous miners; and mining, off-highway, and articulated trucks. Its Energy & Transportation segment offers reciprocating engine powered generator set and engine, integrated system, turbine, centrifugal gas compressor, diesel-electric locomotive and component, and other rail-related products and services. The company's Financial Products segment offers finance for Caterpillar equipment, machinery, and engines, as well as dealers; property, casualty, life, accident, and health insurance; and insurance brokerage services, as well as purchases short-term trade receivables. It's "All Other" operating segments provides parts distribution and digital investments services. The company was formerly known as Caterpillar Tractor Co. and changed its name to Caterpillar Inc. in 1986.
Company description from FinViz.com.
CAT has been alternately ignored or talked down for the last couple years but the shares keep rising. Part of the recent gains came from the guidance. The company has been bitten by the global slowdown in construction since the financial crisis. Then it was hit by the slowdown in the energy sector. Every expected rebound falied to appear and CAT continued to give cautious guidance. That changed over the last several months.
The global economy is rebounding. There are massive construction projects now underway in China and Asia. The Eurozone is also seeing a resurgence in consrtuction. Commodity metals are booming and mines are reopening shuttered capacity and opening new mines. Everything is suddenly positive for CAT and guidance is exploding.
In December they guided for full year 2017 revenues of $38 billion "as a reasonable midpoint expectation." Analyst estimates for earnings of $3.25 were "too optimistic" according to CAT.
In January they guided for $36-$39 billion in revenue and $2.90 in earnings.
In April they guided for $38-$41 billion in revenue and $3.75 in earnings.
In July they guided for $42-$44 billion in revenue and $5 in earnings.
In October they guided for $44 billion and $6.25 in earnings.
In April they guided for revenue from construction at flat to 5%.
In July they guided for 10% to 15% growth.
In October they guided for 20% construction growth.
In April they guided for revenue from mining at 10% to 15%.
In July they guided for 20% to 25% growth.
In October they guided for 30% growth in mining.
In April they guided for energy revenue at flat to 5%.
In July they raised it to 5% to 10%.
In October they raised it to 12%.
At the September 12th investor day meeting the new CEO said they were targeting $55 billion in revenue in 2018 with margins of 14%-17% compared to 12% in 2017. That would take them back to 2014 levels before the bear market in commodity/energy began. That is 28% above 2017 levels. He was careful not to call it a target but said that level was achievable if the current rebound in mining, energy and construction continued.
In late September, CAT reported a global increase in machine sales of 11% for August. Total sales in Asia and the Pacific surged 44%. In their October earnings, they said Asia-Pacific revenue spiked 57%.
After the devastation in Houston, there were new estimates from analysts for 17% or higher revenue growth in construction equipment.
In late October Caterpillar (CAT) reported earnings of $1.95 that nearly quadrupled and blew past estimates for $1.22. That is the kind of earnings beat that should have spiked shares but given CAT's recent string of new highs over the last three months, a lot of excitement was already priced into the stock. Revenue rose 25% to $11.41 billion compared to estimates for $10.61 billion. Construction equipment revenue rose 37% with energy and transportation equipment revenue rising 12%. CAT raised guidance for the full year from $5.00 to $6.25 on revenue of $44 billion. Analysts were expecting $5.29 and $42.94 billion. This was a killer quarter for CAT and this confirms more than anything else that the global economy is beginning to surge.
CAT shares surged to $140 on the earnings. Over the last three weeks the Dow has been moving sideways and so has CAT. Despite the intraday dips in the Dow CAT continues to hold at $136. If the Dow takes a cliff dive over the next couple of weeks, CAT will follow but the 30-day average is $133 and that has been support. I am recommending we buy a December $130 put to hedge against a sudden decline.
Lastly, the S&P futures are negative tonight. If the market opens lower DO NOT enter this position until CAT shares are positive, even if it takes a couple of days. I would rather buy a dip if possible.
Update 12/18: CAT announced a quarterly dividend of 78 cents payable Feb 20th to holders on Jan 22nd. CAT has raised its dividend for 24 consecutive years and has paid quarterly dividends since 1933.
The company said sales rose 26% for the three months ending in November. Asia Pacific sales rose 43%, Europe, Africa and the Middle East rose 32%, North America rose 12%. Latin America sales rose 48% in October. No number was given for November.
Long Feb $140 call @ $5.08, see portfolio graphic for stop loss.
Closed 12/15: Long Dec $130 put @ 77 cents, expired, -.77 loss.
DLTR - Dollar Tree - Company Profile
No specific news. We closed this position at the open on Tuesday and that appears to have been the right move.
Original Trade Description: September 11th.
Dollar Tree, Inc. operates variety retail stores in the United States and Canada. It operates in two segments, Dollar Tree and Family Dollar. The Dollar Tree segment offers merchandise at the fixed price of $1.00. It provides consumable merchandise, including candy and food, and health and beauty care products, as well as everyday consumables, such as household paper and chemicals, and frozen and refrigerated food; various merchandise comprising toys, durable housewares, gifts, stationery, party goods, greeting cards, softlines, and other items; and seasonal goods, which include Valentine's Day, Easter, Halloween, and Christmas merchandise. This segment operates under the under the Dollar Tree and Dollar Tree Canada brands, as well as 11 distribution centers in the United States and 2 in Canada, and a store support center in Chesapeake, Virginia. The Family Dollar segment operates general merchandise discount retail stores that offer consumable merchandise, which comprise food, tobacco, health and beauty aids, household chemicals, paper products, hardware and automotive supplies, diapers, batteries, and pet food and supplies; and home products, including housewares, home decor, and giftware, as well as domestics, such as blankets, sheets, and towels. It also provides apparel and accessories merchandise comprising clothing, fashion accessories, and shoes; and seasonal and electronics merchandise, which include Valentine's Day, Easter, Halloween, and Christmas merchandise, as well as personal electronics that comprise pre-paid cellular phones and services, stationery and school supplies, and toys. This segment operates under the Family Dollar brand, 11 distribution centers, and a store support center in Matthews, North Carolina. As of January 28, 2017, the company operated 14,334 stores in 48 states and the District of Columbia, and 5 Canadian provinces.
Company description from FinViz.com
Dollar Tree reported earnings in late August that rose 36.1% to 99 cents and beat estimates for 87 cents. Revenue of $5.28 billion rose 5.7% and beat estimates for 5.24 billion. Same store sales rose 2.4%. They guided for the full year for revenue of $22.07-$22.28 billion, up from $21,95-$22.25 billion. Earnings guidance of $4.44-$4.60 rose from $4.17-$4.43.
Shares spiked $6 on the earnings and then went through a week of post earnings depression. Shares have firmed and are right on the verge of breaking through resistance to a 9 month high, and probably higher.
Next earnings Nov 21st.
After earnings Raymond James upgraded them from market perform to strong buy. Bernstein upgraded from underperform to market perform. Telset Advisory reiterated an outperform.
Dollar Tree is Amazon proof. With everything in the store $1 or less even Amazon cannot sell and ship items that cheap. Since their acquisition of Family Dollar they now operated 14,334 stores. This is a retail powerhouse and even if the economy weakens, their business will thrive because of the low price point.
Shares are right at resistance at $83.50 and a 5-month high. They are poised for a breakout with the next resistance at $90.
The November options expire several days before earnings so I am going with the January strikes so there is some earnings expectations in the premium when we exit before the event.
Update 11/27: DLTR reported earnings of $1.01 that beat estimates for $90 cents and was well above the 70 cents reported in the year ago quarter. Revenue of $5.32 billion beat estimates for $5.28 billion. For the current quarter, they guided for revenue in the range of $6.32-$6.43 billion and analysts were expecting $6.26 billion. Full year earnings guidance was $4.64-$4.73 and $22.2-$22.31 billion. That is up from $4.44-$4.60 in prior guidance. Analysts were expecting $4.69.
Same store sales (SSS) for the system rose 3.3% and beat estimates for $2.4%. Dollar Tree SSS rose 5.0% and Family Dollar sales rose 1.5%.
Closed 1/2/18: Long Jan $87.50 call @ $3.30, exit $20.66, +$17.36 gain.
HD - Home Depot - Company Profile
No specific news. Shares dipped to within $1 of our stop loss on Tuesday but we escaped to see HD make another new high. Like CAT, this rally will eventually end. I am keeping the stop loss tight because we have a smaller profit cushion with HD.
Original Trade Description: December 18th
The Home Depot, Inc. operates as a home improvement retailer. It operates The Home Depot stores that sell various building materials, home improvement products, and lawn and garden products, as well as provide installation, home maintenance, and professional service programs to do-it-yourself, do-it-for-me (DIFM), and professional customers. The company offers installation programs that include flooring, cabinets, countertops, water heaters, and sheds; and professional installation in various categories sold through its in-home sales programs, such as roofing, siding, windows, cabinet refacing, furnaces, and central air systems, as well as acts as a contractor to provide installation services to its DIFM customers through third-party installers. It primarily serves homeowners; and professional renovators/remodelers, general contractors, handymen, property managers, building service contractors, and specialty tradesmen, such as installers. The company also sells its products through online. It operates through approximately 2,278 stores, including 1,977 in the United States, including the Commonwealth of Puerto Rico, and the territories of the U.S. Virgin Islands and Guam; 182 in Canada; and 119 in Mexico.
The company reported Q3 earnings of $1.84 that rose 15% and beat estimates for $1.81. Revenue rose 8.1% to $25.026 billion, up from $23.154 billion. This beat estimates for $24.523 billion. Same store sales rose 7.9%. HD said the hurricanes added about $282 million in sales but also cost them about $51 million in store damages and inventory shifting costs. The company guided for Q4 revenue growth of 6.3% and same store sales of 6.5%. Those numbers were up from 5.3% and 5.6% in prior guidance. Earnings are expected to grow 14% to $7.36 for the full year, up from prior guidance of $7.29. Full year 2017 sales are expected to be $100.6 billion. They had $8 billion unspent on a $15 billion share repurchase program.
In early December, Home Depot (HD) announced a new $15 billion buyback and raised guidance for annual sales between $114.6-$119.8 billion by the end of 2020. The new repurchase program replaced the existing $15 billion program. The company expects to buy back $8 billion in shares total in 2017 with $2.1 billion in Q4. Since 2002, Home Depot has bought back 1.3 billion shares worth $73 billion.
Home Depot had an effective tax rate of 37% in Q3. Under the new tax plan that would drop to about 23%. Analysts believe this could boost HD's 2018 earnings by as much as 25%. That means their earnings could rise as much as $1.81. They currently have a PE of 25 and that would equate to about a $45 rise in the stock price. However, I would expect that PE to decline somewhat in the conversion.
Shares are already up after their November earnings guidance but I believe they can still go higher. Options are not cheap. In order to get the benefit of the rise in expectations I would like to reach out to May but the options are too expensive but not enough to make a spread worthwhile. I am recommending a March position and hopefully analyst projections will do the work for us.
Earnings are Feb 13th and I would plan to hold over that report because they will give tax guidance at that time.
Update 1/1/18: HD is reportedly talking to XPO Logistics about an acquisition of the $9 billion company. HD uses them to deliver large items like refrigerators and other appliances. There could be a battle with Amazon since that large item shipping is a problem for Amazon.
Long Mar $190 call @ $4.40, see portfolio graphic for stop loss.
UTX - United Technology - Company Profile
UTX dipped but it was only minimal. The stock was upgraded by Goldman from neutral to buy and by RBC Capital from neutral to outperform. I am putting a tight stop on the position. I would close it but the futures are down -4 as I type this. Maybe there will actually be a decline.
Original Trade Description: January 1st
United Technologies Corporation provides technology products and services to building systems and aerospace industries worldwide. Its Otis segment designs, manufactures, sells, and installs passenger and freight elevators, escalators, and moving walkways; and offers modernization products to upgrade elevators and escalators, as well as maintenance and repair services. The company's UTC Climate, Controls & Security segment provides heating, ventilating, air conditioning, and refrigeration solutions, such as controls for residential, commercial, industrial, and transportation applications. This segment offers electronic security products, including intruder alarms, access control systems, and video surveillance systems; fire safety products; and design, installation, system integration, repair, maintenance, monitoring, and inspection services. Its Pratt & Whitney segment supplies aircraft engines for commercial, military, business jet, and general aviation markets; and provides aftermarket maintenance, repair, and overhaul, as well as fleet management services. The company's UTC Aerospace Systems segment provides electric power generation, power management, and distribution systems; air data and aircraft sensing systems; engine control, intelligence, surveillance, and reconnaissance systems; engine components; environmental control systems; fire and ice detection, and protection systems; propeller systems; engine nacelle systems; aircraft lighting and seating, and cargo systems; actuation and landing systems; space products and subsystems; and aftermarket services. United Technologies Corporation offers its services through manufacturers' representatives, distributors, wholesalers, dealers, retail outlets, and sales representatives, as well as directly to customers. United Technologies Corporation was founded in 1934 and is headquartered in Farmington, Connecticut. Company description from FinViz.com
Expected earnings January 23rd.
This play has nothing to do with the fundamentals of UTX. This is strictly a position to capitalize on any early January decline in the Dow. UTX has rallied sharply since September and is currently sitting at a record high. If the recent Dow leaders sell off in January it could be a sharp drop. I would rather have played BA or CAT but their options are double or triple the price on UTX. I am not looking for a big drop but the $123 level is possible.
The S&P futures are up nearly $4 on Monday night so any opening spike on the Dow could give us an ideal fill on this put. This will be a very short-term position as in 1-2 weeks.
Long Feb $125 put @ $1.90. see portfolio graphic for stop loss.
Prices Quoted in Newsletter
At Option Investor, we have a long-standing policy prohibiting the editors and staff from actually trading the individual recommendations in order to conform to SEC rules concerning trades.
The prices quoted in the newsletter are the end of day prices in most cases.
When discussing fills or stops the prices quoted are the bid/ask at the time the entry trigger or exit stop is hit. This is NOT a price that someone on staff actually got using a live order.
For entry/exit points at the market open the prices quoted will be the opening print. The majority of the time readers are able to get a better fill than the opening print because of market maker bias at the open.
For trades with an opening qualification the prices quoted will be the bid/ask at the time the qualification was met.
All of these rules normally produce worse prices than an active trader would normally get. Because they are standardized there may be some cases where a price quoted was better than an actual fill. If you received a price that was dramatically different than what was quoted please let us know.